Clinical studies with colchicine, a blocker of the CCL2-CCR2 axis [44], have demonstrated the efficacy of anti-inflammatory treatment in preventing CVDs, reinforcing the need for further research on the role of the chemokine CCL2 and its receptor, CCR2, in conditions such as hypertension [45]. The gene discussed is CCR2; the disease is Hypertension.